March 23–Osiris Therapeutics Inc., the troubled Columbia-based biotechnology firm that saw its CEO resign last month, said Tuesday it has been notified of a failure to comply with rules for listing on the Nasdaq Stock Market. NASDAQ notified Osiris March 17 that it did not file its annual report for the year ended Dec. 31 […]